Nike slips, FedEx rises following earnings reports Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Clovis Oncology (CLVS) up 15% after the company announced that data from the Phase 3 ARIEL4 study of Rubraca demonstrate that Rubraca significantly improves PFS compared to standard-of-care chemotherapy, including platinum-based chemotherapy, among patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation who have received two or more prior lines of chemotherapy
- Marker Therapeutics (MRKR) up 28% after insider stock purchases and initiation of the stock with an Overweight rating at Cantor Fitzgerald
- FedEx (FDX) up 5% following the company's fiscal Q3 report
- Fisker (FSR) up 12% after announcing it will redeem its outstanding public warrants on a cashless basis
LOWER -
- Idera Pharmaceuticals (IDRA) down 62% after a drug study miss prompts multiple analyst downgrades
- Skillz (SKLZ) down 9% after its 32M share secondary offering priced at $24 per share
- Nike (NKE) down 2% following the company's fiscal Q3 results, which included a revenue miss
Symbols:
NKE FDX IDRA MRKR SKLZ FSR Keywords: Wall Street, Top Stories, Stocks, Pre-market